BLOG

First Participants Dosed in Early Clinical Trial of Inhaled Therapy ARO-ENaC

A Phase 1/2 clinical trial assessing Arrowhead Pharmaceuticals‘ investigational inhaled therapy, ARO-ENaC, for the treatment of cystic fibrosis (CF), has dosed its first participants, the company announced.

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}